Medication Precautions and Safe Medication Guide for Sparsentan

Sparsentan (trade name: FILSPARI) is a new type of oral drug mainly used to treat chronic kidney diseases such as primary immunoglobulin A nephropathy (IgAN). It works by inhibiting both the angiotensinIIreceptor type 1 (AT1) and the endothelinA receptor (ETA), thereby slowing the deterioration of kidney function. However, there are several areas that require special attention when using sparsentane to ensure safe and effective treatment.

1. Assessment and preparation before medication

Before starting sparsentane, the patient needs a thorough evaluation. First, liver function tests, including serum aminotransferase and total bilirubin levels, are performed to rule out abnormal liver function. Second, measure serum potassium levels to ensure they are less than 5.5 mmol/L to reduce the risk of hyperkalemia. In addition, assess the patient's renal function and blood pressure status to ensure they are suitable for use of this drug. All patients must enroll in the FILSPARI REMS (Risk Assessment and Mitigation Strategies) program before starting treatment and follow monitoring requirements during treatment.

2. Dosage adjustment and taking guidance

The initial dose of sparsentane is200 mg once daily, recommended in the morning or evening before meals. On day 15 of treatment, if the patient tolerates it well, the dose can be increased to 400 mg once daily. Tablets should be swallowed whole and not chewed or crushed. If treatment is interrupted, it should be restarted at 200 mg once daily, continued for 14 days and then increased to 400 mg once daily.

3. Common adverse reactions and monitoring

Sparsentine may cause some adverse reactions, common ones include:

Hyperkalemia (increased serum potassium levels)

Hypotension, especially orthostatic hypotension

Peripheral edema (eg, swelling of hands and feet)

dizziness or fainting

anemia

acute kidney injury

Therefore, blood pressure, serum potassium levels, renal function, and edema need to be monitored regularly during treatment. If the above adverse reactions occur, you should communicate with your doctor in time and adjust the treatment plan if necessary.

4. Special groups and taboos

For pregnant women or women who may become pregnant, sparsentin is embryotoxic and may cause harm to the fetus and is therefore contraindicated during pregnancy. Pregnancy tests should be performed before treatment and continued during treatment and for 1month after discontinuation of treatment. In addition, it is recommended to use effective contraception during treatment. Sparsentan should be avoided in patients with abnormal hepatic function, severe hyperkalemia, hypotension, or severe renal insufficiency. During use, patients should avoid taking other drugs that may affect kidney function or blood potassium levels, such as certain nonsteroidal anti-inflammatory drugs (NSAIDs) or potassium-sparing diuretics.

In short, as a new drug for the treatment of IgANIgAN, sparsentane has significant efficacy, but its potential side effects and usage restrictions require strict monitoring and management during the treatment process. Patients should fully communicate with their doctor before use to ensure the best therapeutic effect under the premise of safety.

Reference materials:https://www.drugs.com/